Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer
暂无分享,去创建一个
James Paul | Ignace Vergote | Jalid Sehouli | Nadeem Siddiqui | Dan Cacsire Castillo-Tong | Robert Brown | E. Berns | J. Gallon | H. Gabra | I. Vergote | S. Darb-Esfahani | G. Wisman | J. Sehouli | J. Flanagan | P. Cunnea | C. Kreuzinger | E. Braicu | A. Hergovich | N. Siddiqui | J. Paul | A. Vanderstichele | Robert Brown | James M Flanagan | C. Wilhelm-Benartzi | Hani Gabra | John Gallon | Silvia Darb-Esfahani | D. Castillo-Tong | N. Masrour | Erick W. Loomis | G Bea A Wisman | Adriaan Vanderstichele | Alexander Hergovich | Angela Wilson | Chail Koo | Nahal Masrour | Erick Loomis | Kirsty Flower | Charlotte Wilhelm-Benartzi | Paula Cunnea | Elena Ioana Braicu | Caroline Kreuzinger | Els Mjj Berns | Angela Wilson | Chail Koo | K. Flower | C. Koo | J. Paul | James M. Flanagan | Els MJJ Berns
[1] Robert Brown,et al. Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment? , 2017, Current cancer drug targets.
[2] S. Baylin,et al. Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage. , 2016, Journal of molecular cell biology.
[3] Robert Brown,et al. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer , 2016, Clinical Cancer Research.
[4] E. Berns,et al. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. , 2016, European journal of cancer.
[5] P. Vineis,et al. Hypomethylation of smoking-related genes is associated with future lung cancer in four prospective cohorts , 2015, Nature Communications.
[6] M. Beckmann,et al. Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses , 2016 .
[7] Robert Brown,et al. Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues , 2015, BMC Cancer.
[8] A. Ashworth,et al. Temporal Stability and Determinants of White Blood Cell DNA Methylation in the Breakthrough Generations Study , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[9] N. Zaffaroni,et al. Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells. , 2014, Cancer letters.
[10] Rafael A. Irizarry,et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..
[11] K. Hansen,et al. Functional normalization of 450k methylation array data improves replication in large cancer studies , 2014, Genome Biology.
[12] Peter A. Jones,et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers , 2014, Oncotarget.
[13] Sebastian M. Armasu,et al. Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome , 2014, BMC Medical Genomics.
[14] R. Brown,et al. Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Paolo Vineis,et al. Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. , 2013, Human molecular genetics.
[16] R. Weksberg,et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray , 2013, Epigenetics.
[17] Devin C. Koestler,et al. DNA methylation arrays as surrogate measures of cell mixture distribution , 2012, BMC Bioinformatics.
[18] S. Baylin,et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. , 2011, Cancer cell.
[19] Kenneth P. Nephew,et al. Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.
[20] C. Glass,et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.
[21] J. W. Kim,et al. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. , 2006, Oncology research.
[22] S. Baylin,et al. Double Strand Breaks Can Initiate Gene Silencing and SIRT1-Dependent Onset of DNA Methylation in an Exogenous Promoter CpG Island , 2008, PLoS genetics.
[23] A. Porcellini,et al. DNA Damage, Homology-Directed Repair, and DNA Methylation , 2007, PLoS genetics.
[24] V. O’Brien,et al. Signalling cell cycle arrest and cell death through the MMR System. , 2006, Carcinogenesis.
[25] Alan Gordon,et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.
[26] G. Hirst,et al. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes , 1999, Current Biology.
[27] R. Baan,et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. , 1995, Biochemistry.